Qiagen ( (QGEN) ) has released its Q4 earnings. Here is a breakdown of the information Qiagen presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
QIAGEN N.V. is a leading global company based in the Netherlands, specializing in Sample to Insight solutions for extracting valuable molecular insights from biological samples, primarily serving the Life Sciences and Molecular Diagnostics sectors.
QIAGEN has reported solid growth for the fourth quarter of 2024, exceeding its financial outlook with a net sales increase of 2% to $521 million and adjusted diluted earnings per share (EPS) of $0.61. The company continues to show resilience in its portfolio, with over 85% of sales derived from highly recurring revenues.
Key financial highlights from QIAGEN’s earnings report include a 63% increase in free cash flow to $506 million for the full year 2024, and a positive adjusted operating income margin that improved to 30.6% in Q4 2024. The company’s diagnostic solutions, particularly the QuantiFERON and QIAstat-Dx products, continue to demonstrate double-digit growth. Despite these gains, the company saw a decline in net income and diluted EPS compared to the previous year.
Looking forward to 2025, QIAGEN anticipates a continuation of solid growth trends, projecting about 4% CER sales growth and adjusted diluted EPS of at least $2.28. The company aims to enhance its adjusted operating income margin while managing lower non-operating income contributions.
QIAGEN’s management expresses confidence in achieving its 2028 targets, driven by its differentiated portfolio and disciplined capital allocation, which seeks to strengthen the business and increase returns to shareholders.
